The global blood purification equipment market size was US$ 17570.5 million in 2021. The global blood purification equipment market size is forecast to reach US$ 40094.7 million by 2030, growing at a compound annual growth rate (CAGR) of 9.6% during the forecast period from 2022 to 2030.
An external device or equipment removes toxins, endotoxins, or other impurities from the patient's blood and returns it to the body through a blood collection tube. It is called blood purification. Today, blood purification has become increasingly popular to treat several conditions that are resistant to traditional therapies, such as surgery and drug administration. The most common application of blood purification is hemodialysis.
Factors Influencing Market Growth
Impact Analysis of COVID-19
COVID-19 had a significant impact on the global blood purification equipment market. A surge in research and development practices focused on the potential use of blood purification for limiting COVID-19 transmissions. Several companies have applied to the U.S. Food and Drug Administration for emergency use authorizations (EUAs) to treat patients with COVID-19 with their blood purification equipment. In addition, a number of manufacturers upgraded their blood purification equipment to meet the surge in demand caused by the COVID-19 outbreak.
Regional Insights
North America is forecast to grow at a higher CAGR in the blood purification equipment market during the forecast years. Demographic trends like the growing geriatric population have contributed to the regional growth. The aging population suffers from one or more types of chronic renal diseases, which is forecast to drive market growth. In addition, rising favorable government regulations regarding blood purification equipment may contribute to the market growth in the region.
Leading Competitors
The leading prominent companies profiled in the global blood purification equipment market are:
Scope of the Report
The global blood purification equipment market segmentation focuses on Product Type, End-User, Indication, and Region.
Segmentation based on Product Type
Segmentation based on End-User
Segmentation based on Indication
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 PORTABLE
5.3 STATIONARY
6 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET, BY END-USER
6.1 OVERVIEW
6.2 HOSPITALS AND CLINICS
6.3 DIALYSIS CENTERS
6.4 OTHERS
7 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET, BY INDICATION
7.1 OVERVIEW
7.2 SEPSIS
7.3 RENAL DISEASES
7.4 OTHERS
8 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL BLOOD PURIFICATION EQUIPMENT MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 INFOMED SA
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 B. BRAUN MELSUNGEN AG
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 BAXTER INTERNATIONAL INCORPORATED
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 NIKKISO CO, LIMITED
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 ASAHI KASEI CORPORATION
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 JAFRON BIOMEDICAL CO., LIMITED
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 HEALTHWELL MEDICAL TECH. CO., LIMITED
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8. SWS MEDICAL GROUP
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 FRESENIUS SE AND CO. KGAA
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 KANEKA CORPORATION
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
We Accept
Copyright ©2022 All rights reserved
